[1] MODLIN I M,CHAMPANERIA M C,CHAN A K,et al.A three-decade analysis of 3,911 small intestinal neuroendocrine tumors:the rapid pace of no progress[J].Am J Gastroenterol,2007,102(7):1464-1473.
[2] YALCIN S.Advances in the systemic treatment of pancreatic neuroendocrine tumors[J].Cancer Treat Rev,2011,37(2):127-132.
[3] BURNIK F S,YALCIN S.NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors[J].Chemotherapy,2009,55(5):381-385.
[4] KIM M J,CHOI D W,CHOI S H,et al.Surgical strategies for non-functioning pancreatic neuroendocrine tumours[J].Br J Surg,2012,99(11):1562-1568.
[5] BACCHETTI S,BERTOZZI S,LONDERO A P,et al.Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors:a meta-analysis of observational studies[J].Int J Hepatol,2013,2013:235040.
[6] CUSATI D,ZHANG L,HARMSEN W S,et al.Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver:surgical treatment and outcomes[J].J Am Coll Surg,2012,215(1):117-125.
[7] SUN W,LIPSITZ S,CATALANO P,et al.Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors:Eastern Cooperative Oncology Group Study E1281[J].J Clin Oncol,2005,23(22):4897-4904.
[8] AOKI T,KOKUDO N,KOMOTO I,et al.Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors:an analysis of a multi-center survey in Japan[J].J Gastroenterol,2015,50(7):769-775.
[9] PAVEL M,BAUDIN E,COUVELARD A,et al.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut,midgut,hindgut,and unknown primary[J].Neuroendocrinology,2012,95(2):157-176.
[10] ABBASI S,KASHASHNA A,ALBABA H.Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors:Jordan experience[J].Pancreas,2014,43(8):1303-1305.
[11] KUNZ P L,CATALANO P J,NIMEIRI H S.A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors:A trial of the ECOG-ACRIN Cancer Research Group(E2211)[J].J Clin Oncol,2015,33(15):4145.
[12] TOUMPANAKIS C,CAPLIN M E.Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors[J].Semin Oncol,2013,40(1):56-68.
[13] SONG K B,KIM S C,KIM J H,et al.Prognostic value of somatostatin receptor subtypes in pancreatic neuroendocrine tumors[J].Pancreas,2016,45(2):187-192.
[14] RINKE A,MULLER H H,SCHADE-BRITTINGER C,et al.Placebo-controlled,double-blind,prospective,randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors:a report from the PROMID Study Group[J].J Clin Oncol,2009,27(28):4656-4663.
[15] SHEN C,SHIH Y C,XU Y,et al.Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors:a survival analysis of SEER-Medicare data[J].Cancer Epidemiol Biomarkers Prev,2015,24(11):1656-1665.
[16] ANTHONY L,VINIK A I.Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period[J].Pancreas,2011,40(7):987-994.
[17] SHEN C,XU Y,DASARI A,et al.Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors[J].J Clin Oncol,2015,33(3):392.
[18] CAPLIN M E,PAVEL M,RUSZNIEWSKI P.Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J].N Engl J Med,2014,371(16):1556-1557.
[19] KULKE M H,SHAH M H,BENSON A R,et al.Neuroendocrine tumors,version 1.2015[J].J Natl Compr Canc Netw,2015,13(1):78-108.
[20] RAYMOND E,DAHAN L,RAOUL J L,et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J].N Engl J Med,2011,364(6):501-513.
[21] YAO J C,SHAH M H,ITO T,et al.Everolimus for advanced pancreatic neuroendocrine tumors[J].N Engl J Med,2011,364(6):514-523.
[22] SINGH S,CARNAGHI C,BUZZON R.Efficacy and safety of everolimus in advanced,progressive,nonfunctional neuroendocrine tumors(NET)of the gastrointestinal(GI)tract and unknown primary:a subgroup analysis of the phase III RADIANT-4 trial[J].J Clin Oncol,2016,34(4):315.
[23] HOBDAY T J,QIN R,REIDY-LAGUNES D,et al.Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors[J].J Clin Oncol,2015,33(14):1551-1556.
[24] KATSUTA E,TANAKA S,MOGUSHI K,et al.CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells[J].Int J Oncol,2016,48(2):657-669. |
